{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T17:02:01Z","timestamp":1784912521759,"version":"3.55.0"},"reference-count":19,"publisher":"The Endocrine Society","license":[{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100015794","name":"Foundation for Research and Education Excellence","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015794","id-type":"DOI","asserted-by":"publisher"}]},{"name":"PCOS Challenge"},{"DOI":"10.13039\/100018733","name":"National Polycystic Ovary Syndrome Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018733","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Polycystic ovary syndrome (PCOS), renamed polyendocrine metabolic ovarian syndrome (PMOS), is a common endocrine disorder affecting 4% to 20% of women worldwide. Prior analysis (2006-2015) demonstrated that PCOS\/PMOS received disproportionately less US National Institutes of Health (NIH) funding compared with other chronic disorders of similar prevalence and\/or morbidity, namely rheumatoid arthritis (RA), tuberculosis (TB), and systemic lupus erythematosus (SLE). A number of bipartisan advocacy efforts have been made since.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To determine the impact of current advocacy efforts on NIH funding for PCOS\/PMOS research.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>NIH Research Portfolio Online Reporting Tools were queried.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In 2016-22, mean annual NIH funding for PCOS\/PMOS was $31.8\u2005M vs $262.4\u2005M (RA), $66.1\u2005M (TB), and $420.4\u2005M (SLE), a 48%, 577%, \u221215% and 689% difference, respectively, compared to 2006-2015. In 2016-2022 PCOS\/PMOS research received 533 awards from 16 NIH Institute\/Centers (ICs), with 44.8% of funding arising from the National Institute of Child Health and Human Development, compared with 68.4% in the prior study period. RA, TB, and SLE funding came from 27, 36, and 27 ICs, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In 2016-2022, PCOS\/PMOS research funding by the NIH increased by \u223c50% compared to 2006-2015, albeit still less than the increase and total funding for RA and SLE. There appeared to be greater interest in PCOS\/PMOS by a higher number of ICs. Recent advocacy efforts appear to be associated with increasing NIH funding. However, much remains to be done to address persistent disparities in research funding for this highly prevalent and morbid women's health disorder.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/clinem\/dgag272","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T11:51:59Z","timestamp":1783597919000},"source":"Crossref","is-referenced-by-count":0,"title":["Polycystic ovary syndrome (PCOS)\/polyendocrine metabolic ovarian syndrome (PMOS) research underfunding continues"],"prefix":"10.1210","author":[{"given":"Adrianna N","family":"Tilton","sequence":"first","affiliation":[{"name":"Department of Obstetrics & Gynecology, Heersink School of Medicine, University of Alabama at Birmingham , Birmingham, AL 35294 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sasha","family":"Ottey","sequence":"additional","affiliation":[{"name":"PCOS Challenge: The National Polycystic Ovary Syndrome Association , Atlanta, GA 30308 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Patterson","sequence":"additional","affiliation":[{"name":"PCOS Challenge: The National Polycystic Ovary Syndrome Association , Atlanta, GA 30308 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3917-0483","authenticated-orcid":false,"given":"Ricardo","family":"Azziz","sequence":"additional","affiliation":[{"name":"Department of Obstetrics & Gynecology, Heersink School of Medicine, University of Alabama at Birmingham , Birmingham, AL 35294 ,","place":["USA"]},{"name":"Department of Healthcare Organization & Policy, School of Public Health, University of Alabama at Birmingham , Birmingham, AL 35294 ,","place":["USA"]},{"name":"Department of Medicine, Heersink School of Medicine, University of Alabama at Birmingham , Birmingham, AL 35294 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2026,7,10]]},"reference":[{"issue":"10545","key":"2026072412141989300_dgag272-B1","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1016\/S0140-6736(26)00717-8","article-title":"Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process","volume":"407","author":"Teede","year":"2026","journal-title":"Lancet"},{"issue":"7","key":"2026072412141989300_dgag272-B2","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1210\/clinem\/dgae917","article-title":"The influence of study quality, age, and geographic factors on PCOS prevalence-A systematic review and meta-analysis","volume":"110","author":"Amiri","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2026072412141989300_dgag272-B3","doi-asserted-by":"crossref","first-page":"G43","DOI":"10.1093\/ejendo\/lvad096","article-title":"Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome","volume":"189","author":"Teede","year":"2023","journal-title":"Eur J Endocrinol"},{"key":"2026072412141989300_dgag272-B4","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.85338","article-title":"Direct economic burden of mental health disorders associated with polycystic ovary syndrome: systematic review and meta-analysis","volume":"12","author":"Yadav","year":"2023","journal-title":"Elife"},{"issue":"1","key":"2026072412141989300_dgag272-B5","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1210\/clinem\/dgae527","article-title":"Economic burden of endometrial cancer associated with polycystic ovary syndrome","volume":"110","author":"Pace","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2026072412141989300_dgag272-B6","doi-asserted-by":"crossref","first-page":"4421","DOI":"10.1210\/jc.2017-01415","article-title":"Perspectives on polycystic ovary syndrome: is polycystic ovary syndrome research underfunded?","volume":"102","author":"Brakta","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"2026072412141989300_dgag272-B7"},{"key":"2026072412141989300_dgag272-B8"},{"issue":"6104","key":"2026072412141989300_dgag272-B9","doi-asserted-by":"crossref","DOI":"10.1126\/science.338.6104.181","article-title":"Biomedical research policy. NIH funding shifts with disease lobbying, study suggests","volume":"338","author":"Kaiser","year":"2012","journal-title":"Science"},{"issue":"5","key":"2026072412141989300_dgag272-B10","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1177\/0003122412458509","article-title":"Disease politics and medical research funding: three ways advocacy shapes policy","volume":"77","author":"Best","year":"2012","journal-title":"Am Sociol Rev"},{"key":"2026072412141989300_dgag272-B11","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780190918408.001.0001","volume-title":"Common Enemies: Disease Campaigns in America","author":"Best","year":"2019"},{"issue":"2","key":"2026072412141989300_dgag272-B12","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/acr.24066","article-title":"Accelerating medicines partnership: organizational structure and preliminary data from the phase 1 studies of lupus nephritis","volume":"72","author":"Hoover","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"Supplement_1","key":"2026072412141989300_dgag272-B13","doi-asserted-by":"crossref","first-page":"i4","DOI":"10.1093\/rheumatology\/keac610","article-title":"The global epidemiology of SLE: narrowing the knowledge gaps","volume":"62","author":"Barber","year":"2023","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"2026072412141989300_dgag272-B14","doi-asserted-by":"crossref","first-page":"247.e1","DOI":"10.1016\/j.ajog.2015.12.013","article-title":"Stein and leventhal: 80 years on","volume":"214","author":"Azziz","year":"2016","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"2026072412141989300_dgag272-B15","first-page":"2","article-title":"The polycystic ovary syndrome: the first 150 years of study","volume":"4","author":"Adashi","year":"2022","journal-title":"F S Rep"},{"issue":"2","key":"2026072412141989300_dgag272-B16","first-page":"604","article-title":"Delayed diagnosis and a lack of information associated with dissatisfaction in women with polycystic ovary syndrome","volume":"102","author":"Gibson-Helm","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2026072412141989300_dgag272-B17","doi-asserted-by":"crossref","first-page":"e1759","DOI":"10.1210\/clinem\/dgaf037","article-title":"Population-based vs health system and insurer records: significant underdiagnosis of PCOS","volume":"110","author":"Hatoum","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2026072412141989300_dgag272-B18","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1530\/EC-19-0496","article-title":"Changes in clinical and biochemical characteristics of polycystic ovary syndrome with advancing age","volume":"9","author":"de Medeiros","year":"2020","journal-title":"Endocr Connect"},{"issue":"10","key":"2026072412141989300_dgag272-B19","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10102101","article-title":"The effect of ageing on clinical, hormonal and sonographic features associated with PCOS-A long-term follow-up study","volume":"10","author":"Jacewicz-\u015awi\u0119cka","year":"2021","journal-title":"J Clin Med"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgag272\/68742395\/dgag272.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgag272\/68742395\/dgag272.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T16:14:24Z","timestamp":1784909664000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article\/doi\/10.1210\/clinem\/dgag272\/8729599"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,10]]},"references-count":19,"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgag272","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,10]]},"article-number":"dgag272"}}